EU/3/15/1521 - orphan designation for treatment of malaria
artesunate
OrphanHuman
Overview
On 28 July 2015, orphan designation (EU/3/15/1521) was granted by the European Commission to Dr Ulrich Granzer, Germany, for artesunate for the treatment of malaria.
The sponsorship was transferred to B And O Pharm, France, in June 2020.
Malaria is an infectious disease caused by Plasmodium parasites. There are four species of Plasmodium parasites that may infect humans: P. vivax, P. malariae, P. ovale and P. falciparum. They are transmitted from person to person by the bite of infected Anopheles mosquitoes. Once in the body, the parasites multiply in the liver and then infect and destroy red blood cells.
Transmission mostly occurs in tropical and subtropical regions including parts of the Americas, Asia and Africa. In Europe, malaria mainly affects travellers returning from these areas.
Fever is the major symptom of malaria and the disease must always be suspected when fever occurs during or after travel to an infected area. In addition, flu-like symptoms such as chills, headaches, muscle aches and fatigue commonly occur.
Malaria is a severe and life-threatening disease because of its complications such as cerebral malaria (a deep coma caused by infected red blood cells adhering to blood vessels in the brain), seizures (fits), and lung and kidney problems. Malaria due to P. falciparum is the most severe form and may rapidly lead to complications, especially in children and others with low immunity (protection) to the disease.
At the time of designation, malaria affected not more than 0.3 in 10,000 people per year in the European Union (EU). This was equivalent to a total of not more than 15,000 people* per year, and is below the ceiling for orphan designation, which is 5 people in 10,000 per year. This isbased on the information provided by the sponsor and the knowledge of the Committee for Orphan Medicinal Products (COMP).
*Disclaimer: For the purpose of the designation, the number of patients affected by the condition is estimated and assessed on the basis of data from the European Union (EU 28), Norway, Iceland and Liechtenstein. This represents a population of 512,900,000 (Eurostat 2015).
At the time of designation, several medicines were authorised in the EU to treat malaria, including products containing artemisinin derivatives such as artesunate to be given by mouth. Quinine is the only medicine authorised in the EU that is given into a vein.
The sponsor has provided sufficient information to show that artesunate might be of significant benefit for patients with malaria, mainly because it might improve survival in those suffering from severe, life-threatening malaria. Artesunate on its own given into a vein has been shown in large studies to be more effective than quinine at improving the survival of patients with severe malaria. Artesunate is also tolerated better than quinine. These assumptions will need to be confirmed at the time of marketing authorisation, in order to maintain the orphan status.
Artesunate is a derivative of the naturally occurring substance artemisinin. It is expected to be given by injection into a vein or muscle. Its exact mode of action is not clear, but once it has entered blood cells infected by the parasite, it is expected to interact with human blood components to release substances that damage the membrane of the malaria parasite, thereby killing it.
As artesunate is a well-known anti-malarial agent, the sponsor has provided data in experimental models from the published literature to support its application for orphan designation.
At the time of submission of the application for orphan designation, clinical trials with artesunate in patients with malaria had finished.
At the time of submission, artesunate was authorised in several African and Asian countries for malaria.
At the time of submission, artesunate was not authorised anywhere in the EU for malaria. Orphan designation of artesunate had been granted in the EU and United States for malaria.
In accordance with Regulation (EC) No 141/2000 of 16 December 1999, the COMP adopted a positive opinion on 18 June 2015 recommending the granting of this designation.
- the seriousness of the condition;
- the existence of alternative methods of diagnosis, prevention or treatment;
- either the rarity of the condition (affecting not more than 5 in 10,000 people in the EU) or insufficient returns on investment.
Designated orphan medicinal products are products that are still under investigation and are considered for orphan designation on the basis of potential activity. An orphan designation is not a marketing authorisation. As a consequence, demonstration of quality, safety and efficacy is necessary before a product can be granted a marketing authorisation.
Key facts
- Active substance
- artesunate
- Intended use
- Treatment of malaria
- Orphan designation status
- Positive
- EU designation number
- EU/3/15/1521
- Date of designation
- Sponsor
B And O Pharm
Zac De La Masquere
500 Rue De L Hers
31750 Escalquens
France
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
EMA list of opinions on orphan medicinal product designation
EMA publishes information on orphan medicinal product designation adopted by the Committee for Orphan Medicinal Products (COMP) on the IRIS online platform:
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: